Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc is positioned favorably due to its innovative pipeline targeting serious immune-related diseases, with GRI-0621 showing promising interim data that suggests positive impacts on fibrogenesis and lung function. The company's current valuation appears attractive, with a notable upside potential based on NPV analysis, indicating the stock may offer substantial returns relative to its current price. Additionally, the recent positive interim biomarker data further supports the company's growth prospects and underscores the strength of its therapeutic candidates in addressing significant unmet medical needs.

Bears say

GRI Bio Inc. has reported significant net losses, with a loss of $3.4 million translating to an EPS of $(1.28), which was worse than both internal estimates and consensus forecasts. Furthermore, the company’s second reported net loss of $3.9 million and an EPS of $(7.72) again fell short of expectations, indicating persistent financial challenges. Despite potential growth opportunities, the company faces substantial risks that include liquidity issues, the viability of its product candidates in clinical trials, regulatory approval hurdles, and competitive pressures, leading to a cautious financial outlook.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.